Technology
June 15, 2011 – The U.S. Food and Drug Administration (FDA) said Terumo Cardiovascular Systems Corp. has issued a class I recall for its Coronary Ostia Cannula 10 (25 cm) long. The company said foreign fragments of adhesive and plastic in the cannula tip may embolize, causing arterial injury, hemorrhaging or other serious events requiring unplanned surgery.
June 15, 2011
Technology
June 15, 2011 – The U.S. Food and Drug Administration (FDA) said Maquet Datascope Corp. has issued a class I recall for its System 98/98XT, CS100/CS100i and CS300 Intra-Aortic Balloon Pumps (IABPs) because of a defective fan in the power supply.
June 15, 2011News
June 13, 2011 – Today, GE Healthcare Medical Diagnostics announced results of a study evaluating the cardiopulmonary safety of Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a Food and Drug Administration (FDA)-approved diagnostic ultrasound contrast agent for use in improving suboptimal echocardiograms.
June 14, 2011Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024News
June 14, 2011 – New performance measures for adults with coronary artery disease (CAD) and hypertension were released today by the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), and the American Medical Association (AMA)-convened Physician Consortium for Performance Improvement (PCPI). The measures reflect the standard of care for patients with coronary artery disease and hypertension, and are intended to provide practitioners and institutions with tools to measure and improve care quality.
June 14, 2011
News
June 14, 2011 — Lengthy periods of ambulance diversion are associated with higher mortality rates among patients with time-sensitive conditions, such as acute myocardial infarction. When a patient’s nearest emergency department was on diversion for 12 or more hours, there were higher patient mortality rates at 30 days, 90 days, nine months and one year than when not on diversion, according to a new study in the Journal of the American Medical Association.
June 14, 2011Technology
The American Society of Echocardiography (ASE) and lifeIMAGE today announced a partnership that will give ASE members the ability to exchange medical images and data with anyone, anywhere.
June 14, 2011Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024
News
June 14, 2011 – The first successful Chinese implants of the Edwards SAPIEN XT valve were performed in May.
June 14, 2011
News
June 14, 2011 – An initial animal study of a next-generation transcutaneous C-Pulse Heart Assist System has been completed. The system is made by Sunshine Heart Inc., a global medical device company focused on technologies for Class III/ambulatory Class IV (moderate to severe) heart failure.
June 14, 2011
Technology
June 14, 2011 –FDA has given clearance to AngioViz, a GE application that gives doctors a new visualization of vascular flow on a single image to help them make important decisions during complex interventional radiology procedures.
June 14, 2011Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023Technology
Expanding upon its radiopharmacy platform, GE Healthcare is introducing new tracers to the FASTlab multi-tracer platform, an advanced positron emission tomography (PET) chemistry system on which the company is also developing PET proprietary agents. The system offers a number of significant enhancements to address the ever-evolving challenges of tracer production. With the addition of three new cassettes, users can access and produce FDG phosphate formulation, NaF, FMISO (HPLC free), FLT (HPLC free) and FDG citrate formulation (equivalent to TRACERlab MX standard formulation) on the same platform. For more information: www.gehealthcare.com
June 13, 2011News
Research being presented at Society of Nuclear Medicine’s (SNM) 58th annual meeting shows that molecular imaging is helping to identify and treat a silent killer. A study focusing on hypertrophic cardiomyopathy (HCM) — a cardiovascular disorder that causes a thickening of the heart muscle — is proving that the effects of a genetic mutation may be an important key to understanding the disease. In related research, a treatment called alcohol septal ablation is being revealed as an effective treatment for severe cases of HCM.
June 13, 2011
Technology
June 10, 2011 – The U.S. Food and Drug Administration (FDA) granted Siemens Healthcare 510(k) clearance for the Biograph mMR, the first system worldwide to enable simultaneous whole-body acquisition of data from magnetic resonance (MR) and positron emission tomography (PET).
June 10, 2011Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023News
June 8, 2011 – The U.S. Food and Drug Administration (FDA) has released its list of pre-market approval (PMA) and 510(k) decisions for new or enhanced medical devices from March 2011. The list includes all FDA PMAs , product development protocols (PDP), supplement and notice decisions. This list is generated on a monthly basis.
June 10, 2011
News
June 10, 2011 - A U.S. Food and Drug Administration (FDA) advisory panel is scheduled to review Edwards Lifesciences’ premarket approval (PMA) application for the Sapien transcatheter heart valve on July 20. Edwards submitted a PMA application in the fall of 2010 based on data from the inoperable cohort (Cohort B) of the PARTNER Trial, for approval of this therapy in the treatment of inoperable patients with severe aortic stenosis.
June 10, 2011
News
June 10, 2011 – The U.S. Food and Drug Administration (FDA) announced safety label changes for the cholesterol-lowering medication simvastatin because the highest approved dose – 80 milligram (mg) – has been associated with an elevated risk of muscle injury or myopathy, particularly during the first 12 months of use.
June 10, 2011© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now